Ofelya Gevorgyan is a Rheumatology/Immunology physician. OpenAlex indexes 14 publications with 301 citations (h-index 5).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
315 Martin Luther King Jr Way
Tacoma, WA 984054234
Telephone
253-403-1000Registry record last updated 2 Jul 2019.
Industry payments
12 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Amgen Inc.Program year20242 payments
- ABBVIE INC.Program year20241 payment
- SOBI, INCProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
35.5%Folate Analog Metabolic Inhibitor22.6%Methotrexate100%Part D≥63 patientsAntirheumatic Agent4.2%Leflunomide100%Part D<11 patients+ 3 more classes in this area
Antiparasitic
24.3%Antimalarial24.3%Hydroxychloroquine Sulfate100%Part D≥57 patientsMetabolism & gastrointestinal
24.2%Corticosteroid16.9%Prednisone100%Part D≥45 patientsAntidiarrheal microorganisms7.3%Folic Acid100%Part D≥16 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Anterior uveitis in patients with spondyloarthropathies in a single US academic center: a retrospective study
Rheumatology International
2019 - Retinal vasculitis the first clue in the diagnosis of progressive hemifacial atrophy
European Journal of Rheumatology
2019 - Retinal vasculitis the first clue in the diagnosis of progressive hemifacial atrophy
DOAJ (DOAJ: Directory of Open Access Journals)
2019 - 1854 Conservative Management of Pneumatosis Cystoides Intestinalis With Pneumoperitoneum in a Scleroderma-Related Illness
The American Journal of Gastroenterology
2019
Similar KOLs
Other experts from the same institution or the same specialty.
David J. Hunter
The University of Sydney
Aziz Sheikh
Universiti Malaysia Terengganu
Nima Hafezi‐Nejad
The University of Sydney
Gelin Xu
Second Affiliated Hospital of Nanjing Medical University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”